Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention (STATUS PCI)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2011 by Stony Brook University.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Allen Jeremias, Stony Brook University
ClinicalTrials.gov Identifier:
NCT01464671
First received: October 31, 2011
Last updated: November 2, 2011
Last verified: October 2011

October 31, 2011
November 2, 2011
July 2009
December 2012   (final data collection date for primary outcome measure)
Bleeding events [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
The primary endpoint of the study will be major and minor bleeding events, defined by the REPLACE-2 trial definition during the index hospitalization and up to 30 days post discharge.
Same as current
Complete list of historical versions of study NCT01464671 on ClinicalTrials.gov Archive Site
MACE [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
Major adverse cardiac events (MACE) comprising of all cause mortality, myocardial infarction (MI), ischemia driven target vessel revascularization (TVR), and cerebral vascular accident (CVA).
Same as current
Not Provided
Not Provided
 
Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention
STATUS-PCI: Stable Angina Therapy With Angiomax® or Unfractionated Heparin for patientS Undergoing Percutaneous Coronary Intervention

The objective of the study is to assess the safety and efficacy of Angiomax® (bivalirudin) versus unfractionated heparin (UFH) in patients presenting with stable angina or silent ischemia (positive stress test without chest pain) that undergo percutaneous coronary intervention (PCI).

The primary endpoint of the study will be major and minor bleeding events, defined by the REPLACE-2 trial definition, during the index hospitalization and up to 30 days post discharge.

The purpose of this study is to compare in a randomized, controlled, single-blinded, 1:1 fashion UFH versus bivalirudin in patients with stable angina pectoris or silent ischemia undergoing PCI.

Secondary study endpoints will include:

  • Major adverse cardiac events (MACE) comprising of all cause mortality, myocardial infarction (MI), ischemia driven target vessel revascularization (TVR), and cerebral vascular accident (CVA).
  • Net adverse clinical events (NACE) will be consistent of MACE plus major bleeding as defined by the REPLCE-2 criteria.
  • Cardiac death in-hospital and up to 30 days post discharge.
  • MI in-hospital and up to 30 days post discharge.
  • CVA in-hospital and up to 30 days post discharge.
  • Incidence of all-cause mortality at 6 months and 1 year.
  • MACE at 6 months and 1 year.
  • Incidence of acute (0-24 hours post procedure) stent thrombosis rates.
  • Incidence of sub-acute (24 hours - 30 days) stent thrombosis rates.
  • Length of hospital stay (LOS)
  • Economic analysis (total cost during hospitalization) and up to 30 days post discharge.
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Coronary Artery Disease
  • Drug: Bivalirudin
    Anticoagulation during percutaneous coronary intervention
    Other Name: Angiomax
  • Drug: Heparin
    Anticoagulation during percutaneous coronary intervention
  • Active Comparator: Bivalirudin
    Anticoagulation during percutaneous coronary intervention
    Interventions:
    • Drug: Bivalirudin
    • Drug: Heparin
  • Active Comparator: Unfractionated Heparin
    Anticoagulation during percutaneous coronary intervention
    Intervention: Drug: Heparin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
776
December 2013
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. The patient is male or female ≥ 18 years of age.
  2. The patient presents with stable angina pectoris, or silent ischemia (positive stress test without chest pain).
  3. The patient is scheduled for coronary angiography, with possible angioplasty.
  4. The patient is able to tolerate dual anti-platelet therapy with aspirin and clopidogrel for a minimum of 30 days and is on those medications at the time of the PCI (clopidogrel may be administered during PCI or within 30 minutes post PCI).
  5. The patient is able and willing to conform to the requirements of the study and voluntarily signs an Informed Consent.
  6. The patient does not present with any form of illness or condition that in the investigator's opinion would impair the results of the study.
  7. Women of child bearing potential must have a negative urine or serum pregnancy test prior to enrollment.

Exclusion Criteria:

  1. Patients in cardiogenic shock.
  2. Patients with acute coronary syndrome, which includes unstable angina, non-ST-elevation MI or STEMI.
  3. Known history of heparin-induced thrombocytopenia.
  4. Contraindication to unfractionated heparin, bivalirudin, or any anticoagulant or antithrombotic pharmacological agent.
  5. Any significant medical condition, which in the investigator's opinion, may interfere with the patient's optimal participation in the study.
  6. Pregnant women or nursing mothers.
Both
18 Years and older
No
Contact: Allen Jeremias, MD 631-444-1393 allen.jeremias@stonybrook.edu
United States
 
NCT01464671
119778 (IRB ID)
Yes
Allen Jeremias, Stony Brook University
Stony Brook University
Not Provided
Principal Investigator: Allen Jeremias, MD Stony Brook University
Stony Brook University
October 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP